Dynavax to Present at the JMP Securities Life Sciences Conference
- Futures gain as investors cheer rate cut prospects
- Stocks will be hostage to earnings delivery in 2024 rather than yields - JPMorgan
- General Motors (GM) surges on $10 billion buyback plan, increased dividend
- Bonds bask in talk of Fed interest rate cuts
- Dollar Tree (DLTR) slips as earnings, outlook trail analyst estimates
The presentation will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations.
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the
View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-present-at-the-jmp-securities-life-sciences-conference-301818601.html
SOURCE Dynavax Technologies
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Enbridge Announces 2024 Financial Guidance and 3% Dividend Increase
- The New Flat Rate introduces HVAC Lite price book
- AIRBUS Veteran Vanessa McCall Joins ANSER as CHRO
Create E-mail Alert Related CategoriesPRNewswire, Press Releases
Related EntitiesJMP Securities, Twitter
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!